Teva's turnaround is real -- and may not be over.
The Motley Fool on MSN
Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock.
That's when its first-quarter results will be published.
The market's rediscovery of Teva Pharmaceuticals remains ongoing.
Life Sciences' $400 million commitment to Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) in March could be an example. Blackstone is a giant in the alternative asset management world. Its Blackstone ...
Teva Pharmaceutical Industries Limited’s TEVA stock has risen 12.9% in a month. Teva’s stock mainly gained after it announced first-quarter 2025 results on May 7. Teva’s first-quarter results were ...
After a multi-year slump, Teva Pharmaceutical Industries Limited(NYSE: TEVA) is on a roll. Shares of the Israel-based ...
Teva Pharmaceutical Industries Limited’s TEVA shares have risen 21.6% in three months. Over the past few quarters, Teva has successfully launched several biosimilars and other high-value, complex ...
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) stock is trading higher on Wednesday after the company’s first-quarter 2025 financial results. Here are the details. Teva reported revenue of $3.89 ...
Earnings pop puts Teva’s latest quarter in focus Teva Pharmaceutical Industries (NYSE:TEVA) just released its first quarter 2026 results, with higher sales, net income and earnings per share compared ...
Looking ahead to 2030, our model projects TEVA could trade at an average price of $46.39, with a potential range between $34.79 and $57.99. This represents a potential 36.2% return from today's price.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results